Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Ophthalmology

Long-Term Management and Daily Life

At a Glance

Managing chronic uveitis focuses on keeping the eye quiet while minimizing medication side effects. Long-term success requires routine eye exams to check for silent inflammation and high eye pressure, using steroid-sparing medications when needed, and proactively protecting your mental well-being.

Living with chronic uveitis—defined as inflammation that lasts or recurs for three months or more—requires a shift from “curing” the disease to “managing” it for the long term [1]. Success in this phase means achieving quiescence (a quiet, non-inflamed eye) while minimizing the side effects of treatment and protecting your mental well-being [2][3].

Your Monitoring Schedule

The frequency of your eye exams will change based on how active your disease is. Monitoring for ocular hypertension (high eye pressure) is essential at every visit, regardless of whether you have symptoms [4].

  • During a Flare: You may need to see your specialist every few days or weeks until the inflammation is under control.
  • During Quiescence (Quiet Phase): Once your eye is stable, visits are typically spaced out to every 3 to 6 months. This schedule allows your doctor to catch “silent” inflammation or early signs of complications [2].

Vigilance for Side Effects

Long-term management involves a careful balancing act between controlling uveitis and managing the side effects of corticosteroids [4][5].

1. Steroid-Induced Cataracts

Cataracts (a clouding of the eye’s natural lens) are caused by both the inflammation itself and the steroids used to treat it [6][7]. They are common in chronic patients, especially those using implants or high-dose drops [8][9]. Fortunately, cataract surgery is highly successful in uveitis patients once the eye has been quiet for several months [10].

2. Ocular Hypertension & Glaucoma

Steroids can cause the pressure inside your eye to rise, a condition called ocular hypertension [4][5]. If left untreated, this high pressure can damage the optic nerve, leading to glaucoma. This risk depends on your dose, the type of steroid used, and your individual biology [5][11].

Lifestyle and the Psychological Toll

  • Smoking Cessation: Smoking is a well-established risk factor for uveitis flares and can increase your risk of developing complications like macular edema. Quitting smoking is one of the most proactive steps you can take.
  • Mental Health Support: It is normal to feel significant anxiety or depression when living with a condition that threatens your sight [12][13]. The “waiting for the other shoe to drop” feeling before a potential flare can be exhausting. Because emotional reactions are a major part of the disease burden, many patients find it helpful to work with a counselor or join a support group to manage the stress of chronic illness [12][14].

Staying in Control

You are the most important member of your care team. By tracking your symptoms, attending every monitoring appointment, and using steroid-sparing agents (like adalimumab or mycophenolate) as prescribed, you can significantly reduce your risk of permanent vision loss and improve your long-term outlook [15][16][17]. Your goal is to keep the eye “quiet and white” while leading a full, active life.

Common questions in this guide

How often should I see my eye doctor for chronic uveitis?
During an active flare, you may need appointments every few days or weeks. Once your eye is quiet and stable, visits are typically spaced out to every 3 to 6 months to monitor for silent inflammation.
Can uveitis treatments cause cataracts?
Yes, cataracts can develop from both the chronic inflammation of uveitis and the use of corticosteroid treatments. Fortunately, cataract surgery is highly successful for patients once their eye inflammation has been controlled for several months.
What is ocular hypertension and how does it relate to uveitis?
Ocular hypertension is high pressure inside the eye, which can be triggered by steroid treatments used for uveitis. Left untreated, it can damage the optic nerve and lead to glaucoma, making regular monitoring essential.
How does smoking affect my uveitis?
Smoking is a known risk factor that can trigger uveitis flares and increase your chances of developing complications like macular edema. Quitting smoking is a powerful way to help protect your vision and overall health.
What can I do to cope with the anxiety of living with chronic uveitis?
It is completely normal to experience anxiety or depression when dealing with a vision-threatening condition. Many patients find relief by joining support groups, working with a counselor, and actively tracking their symptoms to feel more in control.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is our target schedule for eye exams now that my inflammation is quiet?
  2. 2.Am I currently showing signs of a 'posterior subcapsular cataract' from my steroid use?
  3. 3.What is my current eye pressure, and how has it changed since I started my current dose of steroids?
  4. 4.If my inflammation returns, what is the fastest way for me to get an emergency evaluation?
  5. 5.Are there local or online support groups you recommend for patients dealing with the anxiety of chronic uveitis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Development of a Consensus Guideline for the Diagnosis and Management of Chronic Noninfectious Uveitis Affecting the Posterior Segment.

    Singh RP, Albini TA, Baumal CR, et al.

    Ophthalmic surgery, lasers & imaging retina 2024; (55(11)):652-658 doi:10.3928/23258160-20240625-01.

    PMID: 39254498
  2. 2

    Behçet's Disease Uveitis.

    Joubert M, Desbois AC, Domont F, et al.

    Journal of clinical medicine 2023; (12(11)) doi:10.3390/jcm12113648.

    PMID: 37297843
  3. 3

    Long-Term Follow-up of Patients With Uveitis Treated With Adalimumab: Response Rates and Reasons for Discontinuation of Therapy.

    Eurelings LEM, Missotten TOAR, van Velthoven MEJ, et al.

    American journal of ophthalmology 2022; (240()):194-204 doi:10.1016/j.ajo.2022.03.017.

    PMID: 35314190
  4. 4

    Risk of Ocular Hypertension in Adults with Noninfectious Uveitis.

    Daniel E, Pistilli M, Kothari S, et al.

    Ophthalmology 2017; (124(8)):1196-1208 doi:10.1016/j.ophtha.2017.03.041.

    PMID: 28433444
  5. 5

    The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis.

    Kothari S, Foster CS, Pistilli M, et al.

    Ophthalmology 2015; (122(10)):1987-2001.

    PMID: 26233626
  6. 6

    Cataract Surgery Complications in Uveitis Patients: A Review Article.

    Llop SM, Papaliodis GN

    Seminars in ophthalmology 2018; (33(1)):64-69 doi:10.1080/08820538.2017.1353815.

    PMID: 29185838
  7. 7

    Do systemic steroids increase the risk of ocular complication in uveitis patients? Focus on a Italian referral center.

    Posarelli C, Talarico R, Vella G, et al.

    Clinical rheumatology 2019; (38(10)):2917-2923 doi:10.1007/s10067-019-04585-3.

    PMID: 31172366
  8. 8

    The 0.2-μg/day Fluocinolone Acetonide Intravitreal Implant in Chronic Noninfectious Posterior Uveitis: A 3-year Randomized Trial in India.

    Biswas J, Tyagi M, Agarwal M,

    Ophthalmology science 2024; (4(1)):100403 doi:10.1016/j.xops.2023.100403.

    PMID: 38027419
  9. 9

    UVEITIS TREATED WITH DEXAMETHASONE IMPLANT.

    Mathis T, Cerquaglia A, Weber M, et al.

    Retina (Philadelphia, Pa.) 2021; (41(3)):620-629 doi:10.1097/IAE.0000000000002901.

    PMID: 32618834
  10. 10

    Cataract Surgery Outcomes in Uveitis: The Multicenter Uveitis Steroid Treatment Trial.

    Sen HN, Abreu FM, Louis TA, et al.

    Ophthalmology 2016; (123(1)):183-90.

    PMID: 26499920
  11. 11

    Risk of Elevated Intraocular Pressure With Difluprednate in Patients With Non-Infectious Uveitis.

    Yakin M, Kumar A, Kodati S, et al.

    American journal of ophthalmology 2022; (240()):232-238 doi:10.1016/j.ajo.2022.03.026.

    PMID: 35381204
  12. 12

    Cross sectional, qualitative thematic analysis of patient perspectives of disease impact in juvenile idiopathic arthritis-associated uveitis.

    Sen ES, Morgan MJ, MacLeod R, et al.

    Pediatric rheumatology online journal 2017; (15(1)):58 doi:10.1186/s12969-017-0189-6.

    PMID: 28778202
  13. 13

    Visual Functioning and Health-related Quality-of-Life are Compromised in Patients with Uveitis.

    Hui MM, Wakefield D, Patel I, et al.

    Ocular immunology and inflammation 2017; (25(4)):486-491 doi:10.3109/09273948.2016.1139734.

    PMID: 27002552
  14. 14

    The Impact of Adult Uveitis on Quality of Life: An Exploratory Study.

    Prem Senthil M, Lim L, Braithwaite T, et al.

    Ophthalmic epidemiology 2021; (28(5)):444-452 doi:10.1080/09286586.2020.1856385.

    PMID: 33345711
  15. 15

    Safety of Mycophenolate Mofetil in the Treatment of Non-Infectious Uveitis and Sclerouveitis in Japanese Patients: A Feasibility Study.

    Hiyama T, Komatsu K, Harada Y

    Ocular immunology and inflammation 2025; (33(7)):1303-1312 doi:10.1080/09273948.2025.2492773.

    PMID: 40262603
  16. 16

    Early Immunosuppressive Therapy and Ocular Complications in Pediatric and Young Adult Patients with Non-Infectious Uveitis at a Tertiary Referral Center in Japan.

    Sada I, Hiyama T, Orihashi Y, et al.

    Ocular immunology and inflammation 2024; (32(10)):2459-2466 doi:10.1080/09273948.2024.2409394.

    PMID: 39436950
  17. 17

    Long-Term Safety and Efficacy of Adalimumab in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.

    Suhler EB, Jaffe GJ, Fortin E, et al.

    Ophthalmology 2021; (128(6)):899-909 doi:10.1016/j.ophtha.2020.10.036.

    PMID: 33157077

This page provides educational information on managing chronic uveitis and its impact on daily life. It does not replace professional medical advice. Always consult your ophthalmologist or specialist for personalized care.

Get notified when new evidence is published on Uveitis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.